Alkem Laboratories Ltd

Alkem Labs FY26 Report: Revenue Hits ₹147,123M, Expands into MedTech 🏥📈

- FY26 Revenue: ₹147,123M (+13.5% YoY), EBITDA: ₹30,052M (20.4% margin).

- Domestic sales: ₹98,514M (+9.7% YoY, 67.8% of total).

- US sales: ₹29,845M (+20.3% YoY, 20.5% of total).

- Non-US international sales: ₹16,964M (+26.7% YoY, 11.7% of total).

- PAT: ₹23,511.6M; Q4 PAT declined 22.7% YoY to ₹2,365M.

- Entered MedTech via Exactech licensing & Bombay Ortho acquisition.

- R&D spend: ₹6,173M (4.2% of revenue); 8 ANDAs & 1 BLA filed.

- Dividend: Proposed ₹10/share (final) + ₹43/share (interim).

- Net cash position: ₹54.74B as of March 2026.

- 18 manufacturing facilities; 192 ANDAs filed in US (167 approvals).